Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.